Trademark: 90171690
Status Date
Wednesday, November 29, 2023
Filing Date
Thursday, September 10, 2020
Published for Opposition
Tuesday, April 13, 2021
40 Custom manufacture of oligonucleotides or RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders
5 Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases
42 Research and development of pharmaceutical products; research and development in the field of bioscience; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; research and development of oligonucleotide compounds for targeted RNA editing; research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders
Nov 30, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 29, 2023
Sou Extension 5 Granted
Nov 29, 2023
Sou Extension 5 Filed
Nov 29, 2023
Sou Teas Extension Received
Jun 2, 2023
Notice Of Approval Of Extension Request E-Mailed
May 31, 2023
Sou Extension 4 Granted
May 31, 2023
Sou Extension 4 Filed
May 31, 2023
Sou Teas Extension Received
May 25, 2023
Teas Change Of Correspondence Received
May 25, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
May 25, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Nov 30, 2022
Notice Of Approval Of Extension Request E-Mailed
Nov 28, 2022
Sou Extension 3 Granted
Nov 28, 2022
Sou Extension 3 Filed
Nov 28, 2022
Sou Teas Extension Received
Jun 7, 2022
Notice Of Approval Of Extension Request E-Mailed
Jun 3, 2022
Sou Extension 2 Granted
Jun 3, 2022
Sou Extension 2 Filed
Jun 3, 2022
Sou Teas Extension Received
Dec 2, 2021
Notice Of Approval Of Extension Request E-Mailed
Nov 30, 2021
Sou Extension 1 Granted
Nov 30, 2021
Sou Extension 1 Filed
Nov 30, 2021
Sou Teas Extension Received
Jun 8, 2021
Noa E-Mailed - Sou Required From Applicant
Apr 13, 2021
Official Gazette Publication Confirmation E-Mailed
Apr 13, 2021
Published For Opposition
Mar 24, 2021
Notification Of Notice Of Publication E-Mailed
Mar 11, 2021
Approved For Pub - Principal Register
Mar 10, 2021
Teas/Email Correspondence Entered
Mar 10, 2021
Correspondence Received In Law Office
Mar 9, 2021
Teas Response To Office Action Received
Mar 9, 2021
Examiner's Amendment Entered
Mar 9, 2021
Assigned To Lie
Mar 9, 2021
Notification Of Examiners Amendment E-Mailed
Mar 9, 2021
Examiners Amendment E-Mailed
Mar 9, 2021
Examiners Amendment -Written
Jan 28, 2021
Notification Of Non-Final Action E-Mailed
Jan 28, 2021
Non-Final Action E-Mailed
Jan 28, 2021
Non-Final Action Written
Jan 21, 2021
Assigned To Examiner
Oct 16, 2020
New Application Office Supplied Data Entered
Sep 14, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
